Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?

Journal of Neuro-Oncology

Volumn 58, Issue 2, 2002, Pages 175-178

  Khan, R B ^a   Shi, W ^a   Thaler, H T ^a   DeAngelis, L M ^a   Abrey, L E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Intrathecal chemotherapy; Methotrexate; Neurotoxicity; Primary CNS lymphoma

Indexed keywords

METHOTREXATE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CASE CONTROL STUDY; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; FEMALE; HUMAN; LEUKOENCEPHALOPATHY; MALE; MENINGOCELE; MOTOR DYSFUNCTION; NEUROTOXICITY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, SPINAL; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; NERVOUS SYSTEM; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036063821     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016077907952     Document Type: Article

References (11)

1. Treatment for primary CNS lymphoma: The next step
2. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas
3. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients
4. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma
5. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases
6. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group
7. Leptomeningeal tumor in primary central nervous system lymphoma: Recognition, significance, and implications
8. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion
9. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non Hodgkin's lymphoma
10. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - A Pediatric Oncology Group study
11. Central nervous system metastases from non-Hodgkin's lymphoma: Treatment and prophylaxis